Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Oct 15, 2026; 18(10): 122724
Published online Oct 15, 2026. doi: 10.4251/wjgo.122724
Published online Oct 15, 2026. doi: 10.4251/wjgo.122724
Prognostic value of the prognostic immune-inflammatory-nutritional score in patients with advanced gastric cancer treated with immunochemotherapy
Qiu-Lin Hao, Zheng-Yu Li, Zhi-Yuan Yao, Yu-Meng Shen, Dong-Shan Sun, Chao Gao, Ran-Ran Jiang, Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China
Co-first authors: Qiu-Lin Hao and Zheng-Yu Li.
Co-corresponding authors: Chao Gao and Ran-Ran Jiang.
Author contributions: Hao QL and Li ZY made equal contributions to writing the original draft as co-first authors; Hao QL, Gao C, and Jiang RR designed the research; Li ZY, Yao ZY, and Shen YM have made contributions to data collection and organization; Sun DS conducted statistical analysis; Gao C and Jiang RR have played important roles in the experimental design as co-corresponding authors; all authors have read and approved the final manuscript.
AI contribution statement: Some text in this manuscript has been edited with the aid of AI tools, solely for language enhancement and proofreading purposes. All authors have carefully reviewed and verified the content generated with the assistance of AI, and bear full responsibility for the scientific content of the manuscript. The AI tools did not participate in the generation of original scientific data, independent scientific analysis, nor were they used to form scientific conclusions.
Supported by the Advanced Program of The Affiliated Hospital of Xuzhou Medical University, No. PYJH2025312; and The Affiliated Hospital of Xuzhou Medical University, No. 2023ZL07.
Institutional review board statement: This study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (approval No. XYFY2023-KL277-01) and was conducted in accordance with the principles of the Declaration of Helsinki.
Informed consent statement: Due to the retrospective nature of this study, the requirement for written informed consent was waived by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Data sharing statement: Data underlying this study are available upon request from the corresponding author at xyfyjrr@126.com.
Corresponding author: Ran-Ran Jiang, MD, PhD, Professor, Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai Road, Xuzhou 221002, Jiangsu Province, China. xyfyjrr@126.com
Received: April 27, 2026
Revised: May 27, 2026
Accepted: June 29, 2026
Published online: October 15, 2026
Processing time: 145 Days and 17.3 Hours
Revised: May 27, 2026
Accepted: June 29, 2026
Published online: October 15, 2026
Processing time: 145 Days and 17.3 Hours
Core Tip
Core Tip: Advanced gastric cancer shows poor prognosis and heterogeneous response to first-line immunochemotherapy. The prognostic immune-inflammatory-nutritional (PIIN) score, combining neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, fibrinogen, albumin-bilirubin, and prognostic nutritional index, independently predicts survival in advanced gastric cancer patients treated with sintilimab plus chemotherapy. Lower PIIN scores correlate with longer progression-free survival, overall survival, and higher disease control. Nomograms integrating PIIN, TNM stage, pro